Literature DB >> 24428792

Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.

Sarah Moran1, Michael O'Keefe, Claire Hartnett, Bernadette Lanigan, John Murphy, Veronica Donoghue.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24428792     DOI： 10.1111/aos.12339

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  13 in total

Review 1.  Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity.

Authors:  Dana Darwish; Ru-Ik Chee; Samir N Patel; Karyn Jonas; Susan Ostmo; J Peter Campbell; Michael F Chiang; R V Paul Chan
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2018-05-29

2.  [Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].

Authors:  H-I Huppertz; H W Lehmann
Journal:  Z Rheumatol       Date:  2014-12       Impact factor: 1.372

3.  Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment.

Authors:  Shilpi H Narnaware; Prashant K Bawankule; Dhananjay Raje
Journal:  J Ophthalmic Vis Res       Date:  2021-07-29

Review 4.  Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.

Authors:  Nita G Valikodath; Michael F Chiang; R V Paul Chan
Journal:  Curr Opin Ophthalmol       Date:  2021-09-01       Impact factor: 4.299

Review 5.  Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.

Authors:  Georgios N Tsiropoulos; Aikaterini K Seliniotaki; Anna-Bettina Haidich; Nikolaos Ziakas; Asimina Mataftsi
Journal:  Int Ophthalmol       Date:  2022-10-10       Impact factor: 2.029

Review 6.  The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.

Authors:  Shing Chuen Chow; Pun Yuet Lam; Wai Ching Lam; Nicholas Siu Kay Fung
Journal:  Eye (Lond)       Date:  2022-01-11       Impact factor: 4.456

Review 7.  Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.

Authors:  Mari Jeeva Sankar; Jhuma Sankar; Parijat Chandra
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

Review 8.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

9.  CLINICAL FEATURES AND OUTCOMES OF INFANTS WITH RETINOPATHY OF PREMATURITY WHO FAIL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Authors:  Lucy T Xu; David A Levine; Amy K Hutchinson; Prethy Rao; George B Hubbard
Journal:  Retina       Date:  2021-11-01       Impact factor: 4.256

Review 10.  Complications of retinopathy of prematurity treatment.

Authors:  Joshua M Barnett; G Baker Hubbard
Journal:  Curr Opin Ophthalmol       Date:  2021-09-01       Impact factor: 4.299
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.